Golidocitnib
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for Golidocitnib, covering 2025-11-18 to 2025-11-18. Get the full timeline:
Most recent: Clinical Trial Update: JAK1 Inhibitor Golidocitnib for the Treatment of Relapsed/Refractory Indolent T/NK-cell Lymphomas [Phase 2]